Axil Capitalは成長著しいバイオメディカルおよびヘルスケア分野への投資に特化したベンチャーキャピタルであり、特にアーリーステージにあるベンチャー企業の成長支援に重きを置いています。
Investment Type: Venture Capital
Portfolio 1
Mentions in press and media 9
| Date | Title | Description |
| 14.07.2026 | FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension | PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million. >> Click here for more f... |
| 11.07.2026 | FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug | FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor... |
| 10.07.2026 | FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib | FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding | Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $67.4M in Series D-2 extension funding. The round was led by SR One, ... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer Therapy | FORE Biotherapeutics Expands Funding for Late-Stage Cancer Program FORE Biotherapeutics has raised $67.4 million to support the development of its lead targeted cancer therapy, plixorafenib. The round was co-led by SR One, Medicxi, SymBiosi... |
| 07.01.2026 | Rakuten Medical: $100 Million Series F Raised To Accelerate U.S. Path For ASP-1929 | Rakuten Medical, a San Diego-based biotechnology company developing its Alluminox platform-based photoimmunotherapy, has closed a $100 million oversubscribed Series F financing to support a global Phase 3 program for its lead investigationa... |
| 17.09.2024 | Pulmotect Raises $5.9M Series C Round Led by Fannin Partners | Funding led by Fannin Partners with participation by Axil Capital provides support for the Company’s Phase 2 Anti-Viral Trial and further development of PUL-042 HOUSTON, TX, UNITED STATES, September 17, 2024 /EINPresswire.com/ -- Pulmotect,... |
| 04.12.2023 | Gexval Co., Ltd. We have implemented a capital increase through third-party allocation. | 0 0 votes Article Rating Connect with Login I allow to create an account When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settin... |
| 04.12.2023 | Gexval Co., Ltd. We have implemented a capital increase through third-party allocation. | Gexval Co., Ltd. We implemented a third-party allotment capital increase. ~Toward accelerating development and adding pipeline additions in Australia~ …… Gexval Co., Ltd. (President and CEO: Juran Kato, location: Fujisawa City, Kanagawa Pre... |